Radiation Oncology Journal

  • 제37권1호
  • /
  • Pages.30-36
  • /
  • 2019
  • /
  • 2234-1900(pISSN)
  • /
  • 2234-3156(eISSN)
대한방사선종양학회 (The Korean Society for Radiation Oncology)
권호 표지
DOI QR코드

DOI QR Code

Maximum standardized uptake value at pre-treatment PET in estimating lung cancer progression after stereotactic body radiotherapy

  • Park, Jisun (Department of Nuclear Medicine, Inje University Busan Paik Hospital, Inje University College of Medicine) ;
  • Choi, Yunseon (Department of Radiation Oncology, Inje University Busan Paik Hospital, Inje University College of Medicine) ;
  • Ahn, Ki Jung (Department of Radiation Oncology, Inje University Busan Paik Hospital, Inje University College of Medicine) ;
  • Park, Sung Kwang (Department of Radiation Oncology, Inje University Busan Paik Hospital, Inje University College of Medicine) ;
  • Cho, Heunglae (Department of Radiation Oncology, Inje University Busan Paik Hospital, Inje University College of Medicine) ;
  • Lee, Ji Young (Division of Hematology and Oncology, Department of Internal Medicine, Busan Paik Hospital, Inje University College of Medicine)
  • 투고 : 2019.01.03
  • 심사 : 2019.03.13
  • 발행 : 2019.03.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: This study aimed to identify the feasibility of the maximum standardized uptake value (SUVmax) on baseline 18F-fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET/CT) as a predictive factor for prognosis in early stage primary lung cancer treated with stereotactic body radiotherapy (SBRT). Materials and Methods: Twenty-seven T1-3N0M0 primary lung cancer patients treated with curative SBRT between 2010 and 2018 were retrospectively evaluated. Four patients (14.8%) treated with SBRT to address residual tumor after wedge resection and one patient (3.7%) with local recurrence after resection were included. The SUVmax at baseline PET/CT was assessed to determine its relationship with prognosis after SBRT. Patients were divided into two groups based on maximum SUVmax on pre-treatment FDG PET/CT, estimated by receiver operating characteristic curve. Results: The median follow-up period was 17.7 months (range, 2.3 to 60.0 months). The actuarial 2-year local control, progression-free survival (PFS), and overall survival were 80.4%, 66.0%, and 78.2%, respectively. With regard to failure patterns, 5 patients exhibited local failure (in-field failure, 18.5%), 1 (3.7%) experienced regional nodal relapse, and other 2 (7.4%) developed distant failure. SUVmax was significantly correlated with progression (p = 0.08, optimal cut-off point SUVmax > 5.1). PFS was significantly influenced by pretreatment SUVmax (SUVmax > 5.1 vs. SUVmax ≤ 5.1; p = 0.012) and T stage (T1 vs. T2-3; p = 0.012). Conclusion: SUVmax at pre-treatment FDG PET/CT demonstrated a predictive value for PFS after SBRT for lung cancer.

키워드

참고문헌

  1. Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006;24:4833-9. https://doi.org/10.1200/JCO.2006.07.5937
  2. Videtic GMM, Donington J, Giuliani M, et al. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline. Pract Radiat Oncol 2017;7:295-301. https://doi.org/10.1016/j.prro.2017.04.014
  3. Kim MS, Kim W, Park IH, et al. Radiobiological mechanisms of stereotactic body radiation therapy and stereotactic radiation surgery. Radiat Oncol J 2015;33:265-75. https://doi.org/10.3857/roj.2015.33.4.265
  4. Chi A, Liao Z, Nguyen NP, Xu J, Stea B, Komaki R. Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: clinical implications. Radiother Oncol 2010;94:1-11. https://doi.org/10.1016/j.radonc.2009.12.008
  5. Pastis NJ Jr, Greer TJ, Tanner NT, et al. Assessing the usefulness of 18F-fluorodeoxyglucose PET-CT scan after stereotactic body radiotherapy for early-stage non-small cell lung cancer. Chest 2014;146:406-11. https://doi.org/10.1378/chest.13-2281
  6. Takeda A, Kunieda E, Fujii H, et al. Evaluation for local failure by 18F-FDG PET/CT in comparison with CT findings after stereotactic body radiotherapy (SBRT) for localized non-smallcell lung cancer. Lung Cancer 2013;79:248-53. https://doi.org/10.1016/j.lungcan.2012.11.008
  7. Clarke K, Taremi M, Dahele M, et al. Stereotactic body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC): is FDG-PET a predictor of outcome? Radiother Oncol 2012;104:62-6. https://doi.org/10.1016/j.radonc.2012.04.019
  8. Burdick MJ, Stephans KL, Reddy CA, Djemil T, Srinivas SM, Videtic GM. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for earlystage non-small-cell lung cancer treated with stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2010;78:1033-9. https://doi.org/10.1016/j.ijrobp.2009.09.081
  9. Na F, Wang J, Li C, Deng L, Xue J, Lu Y. Primary tumor standardized uptake value measured on F18-Fluorodeoxyglucose positron emission tomography is of prediction value for survival and local control in non-smallcell lung cancer receiving radiotherapy: meta-analysis. J Thorac Oncol 2014;9:834-42. https://doi.org/10.1097/JTO.0000000000000185
  10. Dong M, Liu J, Sun X, Xing L. Prognositc significance of SUV(max) on pretreatment (18) F-FDG PET/CT in early-stage non-small cell lung cancer treated with stereotactic body radiotherapy: a meta-analysis. J Med Imaging Radiat Oncol 2017;61:652-9. https://doi.org/10.1111/1754-9485.12599
  11. Lee DS, Kim YS, Yoo IR, et al. Long-term clinical experience of high-dose ablative lung radiotherapy: high pre-treatment [18F]fluorodeoxyglucose-positron emission tomography maximal standardized uptake value of the primary tumor adversely affects treatment outcome. Lung Cancer 2013;80:172-8. https://doi.org/10.1016/j.lungcan.2012.12.023
  12. Lee S, Song SY, Kim SS, et al. Feasible optimization of stereotactic ablative radiotherapy dose by tumor size for stage I non-small-cell lung cancer. Clin Lung Cancer 2018;19:e253-e261. https://doi.org/10.1016/j.cllc.2017.11.001
  13. Park S, Urm S, Cho H. Analysis of biologically equivalent dose of stereotactic body radiotherapy for primary and metastatic lung tumors. Cancer Res Treat 2014;46:403-10. https://doi.org/10.4143/crt.2013.168
  14. Baumann P, Nyman J, Hoyer M, et al. Outcome in a prospective phase II trial of medically inoperable stage I nonsmall-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 2009;27:3290-6. https://doi.org/10.1200/JCO.2008.21.5681
  15. Fakiris AJ, McGarry RC, Yiannoutsos CT, et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys 2009;75:677-82. https://doi.org/10.1016/j.ijrobp.2008.11.042
  16. Onishi H, Araki T, Shirato H, et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 2004;101:1623-31. https://doi.org/10.1002/cncr.20539
  17. Senthi S, Lagerwaard FJ, Haasbeek CJ, Slotman BJ, Senan S. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. Lancet Oncol 2012;13:802-9. https://doi.org/10.1016/S1470-2045(12)70242-5
  18. Bradley JD, El Naqa I, Drzymala RE, Trovo M, Jones G, Denning MD. Stereotactic body radiation therapy for early-stage nonsmall-cell lung cancer: the pattern of failure is distant. Int J Radiat Oncol Biol Phy. 2010;77:1146-50. https://doi.org/10.1016/j.ijrobp.2009.06.017
  19. Palussiere J, Chomy F, Savina M, et al. Radiofrequency ablation of stage IA non-small cell lung cancer in patients ineligible for surgery: results of a prospective multicenter phase II trial. J Cardiothorac Surg 2018;13:91. https://doi.org/10.1186/s13019-018-0773-y
  20. Bollineni VR, Widder J, Pruim J, Langendijk JA, Wiegman EM. Residual 18F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control. Int J Radiat Oncol Biol Phys 2012;83:e551-5. https://doi.org/10.1016/j.ijrobp.2012.01.012
  21. Hoopes DJ, Tann M, Fletcher JW, et al. FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-smallcell lung cancer. Lung Cancer 2007;56:229-34. https://doi.org/10.1016/j.lungcan.2006.12.009

피인용 문헌

  1. Impact of positron emission tomography with computed tomography for image-guided radiotherapy vol.24, pp.5, 2019, https://doi.org/10.1016/j.canrad.2020.03.006